Header Logo

Connection

YOCHAI BIRNBAUM to Rats, Sprague-Dawley

Back to Details
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Rats, Sprague-Dawley.
YOCHAI BIRNBAUM
Connection Strength
1.460
Rats, Sprague-Dawley
  1. Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury. Cardiovasc Drugs Ther. 2023 08; 37(4):625-646.
    View in: PubMed
    Score: 0.140
  2. Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat. Cardiovasc Drugs Ther. 2023 04; 37(2):221-224.
    View in: PubMed
    Score: 0.135
  3. Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Cell Physiol Biochem. 2019; 53(6):961-981.
    View in: PubMed
    Score: 0.113
  4. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015 Aug; 35(8):1805-14.
    View in: PubMed
    Score: 0.088
  5. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014 Sep; 34(9):2078-85.
    View in: PubMed
    Score: 0.083
  6. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc Drugs Ther. 2010 Dec; 24(5-6):391-9.
    View in: PubMed
    Score: 0.064
  7. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H153-64.
    View in: PubMed
    Score: 0.062
  8. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
    View in: PubMed
    Score: 0.061
  9. Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone. Cardiovasc Drugs Ther. 2008 Dec; 22(6):429-36.
    View in: PubMed
    Score: 0.055
  10. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol. 2008 Sep 01; 181(5):3515-23.
    View in: PubMed
    Score: 0.055
  11. Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat. Cardiovasc Drugs Ther. 2008 Aug; 22(4):275-82.
    View in: PubMed
    Score: 0.053
  12. Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther. 2008 Mar; 13(1):72-9.
    View in: PubMed
    Score: 0.053
  13. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007 Oct; 21(5):321-30.
    View in: PubMed
    Score: 0.052
  14. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H813-8.
    View in: PubMed
    Score: 0.050
  15. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007 Jun; 292(6):H2891-7.
    View in: PubMed
    Score: 0.049
  16. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):89-98.
    View in: PubMed
    Score: 0.049
  17. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006 Sep; 291(3):H1158-69.
    View in: PubMed
    Score: 0.047
  18. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther. 2006 Feb; 20(1):27-36.
    View in: PubMed
    Score: 0.046
  19. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1960-8.
    View in: PubMed
    Score: 0.046
  20. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005 Feb 01; 65(2):345-55.
    View in: PubMed
    Score: 0.043
  21. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis. 2004 Feb; 15(1):53-8.
    View in: PubMed
    Score: 0.040
  22. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther. 2003 Jan; 17(1):25-30.
    View in: PubMed
    Score: 0.037
  23. Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. Hypertension. 2013 May; 61(5):1008-13.
    View in: PubMed
    Score: 0.019
  24. Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H376-84.
    View in: PubMed
    Score: 0.012
  25. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res. 1998 Jul; 39(1):216-23.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.